Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Research & Development (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Research & Development for 6 consecutive years, with $52.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 7.26% to $52.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.7 million through Dec 2025, down 7.53% year-over-year, with the annual reading at $158.7 million for FY2025, 7.53% down from the prior year.
  • Research & Development hit $52.2 million in Q4 2025 for Lyell Immunopharma, up from $28.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $52.2 million in Q4 2025 to a low of $19.3 million in Q4 2021.
  • Historically, Research & Development has averaged $40.6 million across 5 years, with a median of $42.4 million in 2022.
  • Biggest YoY gain for Research & Development was 19185.0% in 2021; the steepest drop was 52.19% in 2021.
  • Year by year, Research & Development stood at $19.3 million in 2021, then surged by 97.21% to $38.0 million in 2022, then increased by 23.57% to $47.0 million in 2023, then increased by 3.56% to $48.7 million in 2024, then grew by 7.26% to $52.2 million in 2025.
  • Business Quant data shows Research & Development for LYEL at $52.2 million in Q4 2025, $28.2 million in Q3 2025, and $34.9 million in Q2 2025.